Ftse Mib
36.291,22
0,25%
DAX
21.304,80
-0,38%
S&P 500
6.011,94
-1,46%
NASDAQ
19.366,77
-2,94%
Bitcoin
101.586,00
-2,91%
Pepperstone
Advertisement
Registration Strip Icon for discussion Registrati per interagire nei nostri forum attivi per discutere con investitori con idee simili.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ RAPT Therapeutics Inc (RAPT) RAPT Therapeutics Inc (RAPT) Notizie

RAPT

RAPT Therapeutics (RAPT)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:RAPT
DataOraFonteTitoloSimboloCompagnia
21/01/202522:58Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:RAPTRAPT Therapeutics Inc
13/01/202522:17Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RAPTRAPT Therapeutics Inc
09/01/202514:00GlobeNewswire Inc.RAPT Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceNASDAQ:RAPTRAPT Therapeutics Inc
07/01/202500:38Edgar (US Regulatory)Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:RAPTRAPT Therapeutics Inc
06/01/202514:00GlobeNewswire Inc.RAPT Therapeutics Names Lori Lyons-Williams Chair of the Company’s Board of DirectorsNASDAQ:RAPTRAPT Therapeutics Inc
03/01/202520:08Edgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:RAPTRAPT Therapeutics Inc
23/12/202413:10GlobeNewswire Inc.RAPT Therapeutics Announces $150 Million Private PlacementNASDAQ:RAPTRAPT Therapeutics Inc
23/12/202413:00GlobeNewswire Inc.RAPT Therapeutics and Shanghai Jemincare Pharmaceutical Announce Exclusive License Agreement for Novel Long-Acting anti-IgE AntibodyNASDAQ:RAPTRAPT Therapeutics Inc
14/11/202415:39Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:RAPTRAPT Therapeutics Inc
12/11/202414:00GlobeNewswire Inc.RAPT Therapeutics Reports Third Quarter 2024 Financial ResultsNASDAQ:RAPTRAPT Therapeutics Inc
11/11/202414:00GlobeNewswire Inc.Based on Recent FDA Feedback RAPT Therapeutics Stops Zelnecirnon Program Following Clinical Hold Due to Single SAE of Severe Liver InjuryNASDAQ:RAPTRAPT Therapeutics Inc
08/08/202414:10Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:RAPTRAPT Therapeutics Inc
08/08/202414:00GlobeNewswire Inc.RAPT Therapeutics Reports Second Quarter 2024 Financial ResultsNASDAQ:RAPTRAPT Therapeutics Inc
24/05/202400:19Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RAPTRAPT Therapeutics Inc
09/05/202414:00GlobeNewswire Inc.RAPT Therapeutics Reports First Quarter 2024 Financial ResultsNASDAQ:RAPTRAPT Therapeutics Inc
09/04/202418:00GlobeNewswire Inc.RAPT Therapeutics Announces Promising Results from Phase 2 Trial of Tivumecirnon in Combination with Anti-PD-1 Immunotherapy in CPI-Experienced Head and Neck Cancer PatientsNASDAQ:RAPTRAPT Therapeutics Inc
07/03/202422:15Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:RAPTRAPT Therapeutics Inc
07/03/202414:08Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:RAPTRAPT Therapeutics Inc
07/03/202414:00GlobeNewswire Inc.RAPT Therapeutics Reports Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:RAPTRAPT Therapeutics Inc
05/03/202422:30GlobeNewswire Inc.RAPT Therapeutics Announces Multiple Late-Breaking Presentations at the Upcoming American Association for Cancer Research (AACR) Annual MeetingNASDAQ:RAPTRAPT Therapeutics Inc
20/02/202413:30GlobeNewswire Inc.RAPT Therapeutics Announces Clinical Hold on Studies Evaluating ZelnecirnonNASDAQ:RAPTRAPT Therapeutics Inc
14/02/202414:52Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:RAPTRAPT Therapeutics Inc
13/02/202414:00GlobeNewswire Inc.RAPT Therapeutics Bolsters Leadership Team with the Appointment of Nipun Davar, Ph.D., as Senior Vice President of Technical OperationsNASDAQ:RAPTRAPT Therapeutics Inc
31/01/202414:00GlobeNewswire Inc.RAPT Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology ConferenceNASDAQ:RAPTRAPT Therapeutics Inc
02/01/202414:00GlobeNewswire Inc.RAPT Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:RAPTRAPT Therapeutics Inc
27/11/202314:00GlobeNewswire Inc.RAPT Therapeutics Announces Publication of Phase 1a/1b Clinical Trial of Zelnecirnon (RPT193) to Treat Atopic Dermatitis in AllergyNASDAQ:RAPTRAPT Therapeutics Inc
13/11/202314:00GlobeNewswire Inc.RAPT Therapeutics Reports Third Quarter 2023 Financial ResultsNASDAQ:RAPTRAPT Therapeutics Inc
03/11/202317:00GlobeNewswire Inc.RAPT Therapeutics Announces Positive Data, Including Objective Response Rates and Progression-Free Survival, from its Phase 2 Trial of FLX475 in Combination with a Checkpoint Inhibitor in Patients with Advanced NSCLCNASDAQ:RAPTRAPT Therapeutics Inc
01/11/202321:05GlobeNewswire Inc.RAPT Therapeutics to Participate in Several Upcoming Investor Conferences in NovemberNASDAQ:RAPTRAPT Therapeutics Inc
23/10/202322:40Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:RAPTRAPT Therapeutics Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:RAPT

La tua Cronologia

BIT
BMPS
Banca Monte Dei Paschi D...
BIT
UCG
Unicredit
BIT
PRY
Prysmian
BIT
ISP
Intesa Sanpaolo
BIT
ENEL
Enel
BIT
STMMI
ST Microelectronics
BIT
RACE
Ferrari NV
BIT
STLAM
Stellantis NV
BIT
G
Generali
BIT
MB
Mediobanca Banca di Cred...
BIT
ENI
Eni
BIT
BAMI
Banco BPM
BIT
LDO
Leonardo
BIT
SRG
Snam
BIT
BPE
Bper Banca
BIT
SPM
Saipem
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network